Newsfeeds Archive - Page 14 of 194

1 minute read

News

Hookipa Pharma Announced Additional Preliminary Phase 2 Data On HB-200 In Combination with Pembrolizumab; 42% Objective Response Rate Among 19 Evaluable Patients With With HPV16+ Head And Neck Cancers

October 22, 10:27 AM

HOOKIPA Pharma Inc. (NASDAQ:HOOK, &lsquo, HOOKIPA&rsquo, )), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today presented updated data from its ongoing Phase 2

HOOK

1 minute read

News

AstraZeneca Announced Datopotamab Deruxtecan Plus Imfinzi Demonstrated Robust And Durable Tumour Responses In 1st-line Treatment Of Patients With Metastatic Triple-negative Breast Cancer In BEGONIA Phase Ib/ii Trial.

By Charles Gross

October 22, 7:44 AM

Updated results from the BEGONIA Phase Ib/II trial for the cohort of patients treated with datopotamab deruxtecan (Dato-DXd) plus Imfinzi (durvalumab) (Arm 7) showed that the combination demonstrated durable tumour

AZN

1 minute read

News

Harpoon Therapeutics Announced Confirmed Response Rate 35% (11/31), Across All Tumor Types And Patient Cohorts Treated With 1 Mg Priming Dose, Including Three Confirmed, Complete Responses In Phase 1/2 Clinical Trial of T Cell Engager HPN328

By Charles Gross

October 21, 2:09 PM

Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating

HARP

1 minute read

News

ORIC Pharmaceuticals Announced Initial Phase 1 Dose Escalation Data Of ORIC-114 In Patients With EGFR And HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

By Charles Gross

October 21, 9:28 AM

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced initial data from the ongoing ORIC-114 Phase

ORIC

1 minute read

News

Immunocore Announced KIMMTRAK Demonstrated Long-Term Survival Benefit In HLA-A*02:01 Positive Patients With Previously Untreated Metastatic Uveal Melanoma

By Charles Gross

October 21, 9:25 AM

Immunocore Holdings plc (NASDAQ:IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases,

IMCR

1 minute read

News

Regeneron Announced 89% Estimated Event-free Survival At One Year Among Patients With Stage II To IV Resectable Cutaneous Squamous Cell Carcinoma Who Received Libtayo Prior To Surgery In A Phase 2 Trial

By Charles Gross

October 21, 9:21 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as a neoadjuvant monotherapy in

REGN

2 minute read

Events
News

ESSA Pharma Announced Data Combination Of Masofaniten Plus Enzalutamide Continues To Be Well Tolerated With Deep And Durable Reductions In PSA In Patients With Metastatic Castration-Resistant Prostate Cancer

By Charles Gross

October 21, 9:17 AM

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the

EPIX

1 minute read

News

Lilly Announced Nearly 80% Of Patients With Moderate-to-severe Atopic Dermatitis Maintained Clear Or Almost Clear Skin With Lebrikizumab Monthly Maintenance Dosing At Two Years

By Charles Gross

October 20, 6:49 AM

Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with

LLY

1 minute read

On October 16, 2023, Aligos Therapeutics Entered Into Settlement Agreement With Janssen Biotech Providing For Resolution Of Previously Disclosed Action Brought By Janssen Alleging Breach Of Contract Aligos CEO, Others

By Charles Gross

October 18, 8:53 AM

8-k - On October 16, 2023, Aligos Therapeutics, Inc. (the “Company”) entered into a settlement agreement (the “Settlement Agreement”) withJanssen Biotech, Inc. (successor in interest to Janssen

ALGS

2 minute read

News

InterCure Provided Update Regarding Security Situation In Israel

By Charles Gross

October 17, 5:07 PM

InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the

INCR